

Prof. Dr. Andreas Dietz, *25.11.1962

Head/Direktor
ENT-Clinic
University of Leipzig, Germany
Liebigstraße 10-14, 04103 Leipzig
Phone: (03 41) 97 - 2 17 00
Email: andreas.dietz@medizin.uni-leipzig.de



Since April 2004, Prof. Dr. Andreas Dietz is Chair of the ENT University Clinic Leipzig. He is full-trained ENT and head and neck surgeon and has special qualification in plastic surgery and Oncology. His scientific work is reflected in numerous studies and translational projects on head and neck cancer.

He is internationally known as an expert in this field. He was President of the German Society for ENT - Head and Neck Surgery (DGHNO-KHT) from 2019 to 2020 and is speaker of the interdisciplinary group of Head and Neck Cancer of the German Cancer Society (IAG-KHT).

He holds visible positions on numerous international committees like membership of the Board of Directors of the European Head and Neck Society. He is speaker of the board of the Innovation Center for Computer-Assisted Surgery (ICCAS) Leipzig. He is a member of the Board of Directors of the Global Online Fellowship Initiative at Sloan Kettering Memorial Cancer Center in New York and Chair of the Surgery Subcommittee of the EORTC Head and Neck Group.

He is honorary member of the Royal Belgian, the Austrian, Hungarian, Czech ENT Society and the Indian Head and Neck Foundation. Andreas Dietz is author/co-author of more than 800 pub-med listed publications (h-index 56). He coordinates the German S3-Guideline for oropharyngeal and hypopharyngeal cancer. Andreas Dietz was honored with the DGHNO-KHC Medal of Merit, the Order of Merit of the Free State of Saxony in 2022 and with the EHNS Award in 2023.

Leipzig, 11.04.2025

A handwritten signature in blue ink, consisting of stylized, cursive letters that appear to read 'A. Dietz'.

Prof. Dr. Andreas Dietz

Educational and professional experience

Since 2004	Chairman and Professor at the ENT-Department, University of Leipzig, Germany
1995-2004	Consultant at the Department of Otolaryngology, Head and Neck Surgery of University of Heidelberg
2000	Assistant Professor of Department of Otolaryngology, Head and Neck Surgery of University of Heidelberg
1992-1995	Training and Appointment for specialist of Otolaryngology at the Department of Otolaryngology, Head and Neck Surgery of University of Heidelberg
1991	Medical Doctors (M.D.) degree at University of Heidelberg; Risk Factors in Head and Neck Cancer

Membership in advisory / editorial boards / reviewer

2025	Conference president ECHNO 2027 in Berlin. Member of „Board of Direktors“ European Head and Neck Society (EHNS)
2022	Vice director new comprehensive Cancer Center University hospital Leipzig
2022	Coordinator German S3-Guideline for oropharyngeal and hypopharyngeal cancer within the German Oncologic Cancer Guideline Program.
2019 - 2021	President German ENT-Society (DGHNO-KHC)
2018	Elected member of „Board of Direktors“ European Head and Neck Society (EHNS)
2018	„incoming Präsident“ elect of „Deutschen HNO-Gesellschaft (DGHNO-KHC)“ 2019-2020
Since 2016	Elected as chair of Interdisciplinary Study group Head and Neck Tumors (German Cancer Society (IAG KHT of DKG) and “Tumorzentrum Leipzig”, regional cancer registry of all cancer treating hospitals around Leipzig
2014	Member of the Board of Directors of the Global Online Fellowship Initiative at Sloan Kettering Memorial Cancer Center in New York
2013	Elected as member of the presidential council of the German Society for otorhinolaryngology, head and neck surgery
2009	Call as chair of the Head-Department, University of Leipzig (the department collects the clinics Ophthalmology, ENT, Maxillofacial and Dental/Oral care)
2008	Call as member for the scientific council of the European Laryngeal Society (ELS)
2006	Additional qualification for medical oncology treatment in Head and Neck cancer and appointment as main examiner of this field in Saxonia
2005	Appointment as advisory expert of “Deutschen Verbands für Kehlkopfloose und Kehlkopfooperierte e.V.”

Awards and Recognitions

- honorary member of the Royal Belgian ENT-Society,
- honorary member of the Austrian ENT-Society,
- honorary member of the Hungarian ENT-Society,
- honorary member of the Czech ENT Society

- honorary member of the Indian Head and Neck Foundation
- 2022 Order of Merit of the Free State of Saxony
- 2023 EHNS Award
- 2023 Order of Merit of the German ENT-Society
- 2023 „Consultant Professor“ of ENT-clinic FUDAN-University Shanghai, China

Scientific and Editorial Boards

- Editor Laryngo-Rhino-Otologie (Thieme Deutschland)
- Editor Section of Oncology, Frontiers in Oncology
- Editorial Board "Orale Onkologie"
- Editorial Board "Der Onkologe"
- Editorial Board "European Archives of Otorhinolaryngology" (Springer Deutschland)
- Editorial Board "The EPMA Journal" (Springer Deutschland)
- Editorial Board „Deutsches Ärzteblatt“

Publication list (10 most relevant publications in last five years)

1. **Dietz A**, Wichmann G, Kuhnt T, Pfreundner L, Hagen R, Scheich M, Kölbl O, Hautmann MG, Strutz J, Schreiber F, Bockmühl U, Schilling V, Feyer P, de Wit M, Maschmeyer G, Jungehülsing M, Schroeder U, Wollenberg B, Sittel C, Münter M, Lenarz T, Klussmann JP, Guntinas-Lichius O, Rudack C, Eich HT, Foerg T, Preyer S, Westhofen M, Welkoborsky HJ, Esser D, Thurnher D, Remmert S, Sudhoff H, Görner M, Bünzel J, Budach V, Held S, Knödler M, Lordick F, Wiegand S, Vogel K, Boehm A, Flentje M, Keilholz U. Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II. Ann Oncol. 2018 Oct 1; 29(10):2105-2114.
2. Wichmann G, Rudolph J, Henger S, Engel C, Wirkner K, Wenning JR, Zeynalova S, Wiegand S, Loeffler M, Wald T, **Dietz A**. Is High-Risk Sexual Behavior a Risk Factor for Oropharyngeal Cancer? Cancers (Basel). 2023 Jun 26;15(13):3356. doi: 10.3390/cancers15133356. PMID: 37444466; PMCID: PMC10340603.
3. Mehanna H, Hardman JC, Shenson JA, Abou-Foul AK, Topf MC, AlFalasi M, Chan JYK, Chaturvedi P, Chow VLY, **Dietz A**, Fagan JJ, Godballe C, Golusiński W, Homma A, Hosal S, Iyer NG, Kerawala C, Koh YW, Konney A, Kowalski LP, Kraus D, Kuriakose MA, Kyrodimos E, Lai SY, Leemans CR, Lennon P, Licitra L, Lou PJ, Lyons B, Mirghani H, Nichols AC, Paleri V, Panizza BJ, Parente Arias P, Patel MR, Piazza C, Rischin D, Sanabria A, Takes RP, Thomson DJ, Uppaluri R, Wang Y, Yom SS, Zhu YM, Porceddu SV, de Almeida JR, Simon C, Holsinger FC. Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic:

- an international consensus. *Lancet Oncol.* 2020 Jul;21(7):e350-e359. doi: 10.1016/S1470-2045(20)30334-X. Epub 2020 Jun 11. PMID: 32534633; PMCID: PMC7289563.
4. Sorge I, Hirsch FW, Fuchs M, Gräfe D, **Dietz A**, Sorge M. Imaging in children with hearing loss. *Rofo.* 2023 Oct;195(10):896-904. English, German. doi: 10.1055/a-2081-4119. Epub 2023 Jun 22. PMID: 37348530.
 5. Ambrosch P, Meuret S, **Dietz A**, Fazel A, Fietkau R, Tostmann R, Schroeder U, Lammert A, Künzel J, Jäckel MC, Boeger D, Scherl C, Deitmer T, Breitenstein K, Delank KW, Hilber H, Vester S, Knipping S, Harreus U, Scheich M, Bartel S, Plontke SK, Koscielny S, Veit JA, Greve J, Schilling V, Linxweiler M, Weiß S, Psychogios G, Arens C, Wittekindt C, Oeken J, Grosheva M, Borzikowsky C. Transoral laser microsurgery for supraglottic carcinomas: results of a prospective multicenter trial (SUPRATOL). *Front Oncol.* 2024 Sep 20;14:1440024. doi: 10.3389/fonc.2024.1440024. PMID: 39372873; PMCID: PMC11449847.
 6. Autoren im Auftrag des Ärzteverbandes Deutscher Allergologen (AeDA), des Deutschen Berufsverbandes der HNO-Ärzte (BVHNO) und der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Halschirurgie (DGHNO-KHC); Klimek L, Förster-Ruhrmann U, Becker S, Chaker A, Huppertz T, Deitmer T, Olze H, Strieth S, Wrede H, Schlenter W, Löhler J, Wollenberg B, Beule AG, Rudack C, Bachert C, **Dietz A**. Stellungnahme zur Anwendung von Glukokortikosteroiden bei entzündlichen Erkrankungen der oberen Atemwege (u.a. allergische Rhinitis/chronische Rhinosinusitis) während der aktuellen COVID-19-Pandemie - Empfehlungen des Ärzteverbandes Deutscher Allergologen (AeDA), des Deutschen Berufsverbandes der HNO-Ärzte (BVHNO) und der AGs Klinische Immunologie, Allergologie und Umweltmedizin und Rhinologie und Rhinochirurgie der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Halschirurgie (DGHNO-KHC). *Laryngorhinootologie.* 2020 May;99(5):280-281. German. doi: 10.1055/a-1148-3553. Epub 2020 Mar 31. PMID: 32232815.
 7. Wichmann G, Wald T, Zebralla V, Stoehr M, Pirlich M, Wiegand S, Kunz V, **Dietz A**. Superior 125-month outcome through cetuximab in the larynx organ preservation trial DeLOS-II: a single study center's experience. *Front Oncol.* 2024 Dec 24;14:1506840. doi: 10.3389/fonc.2024.1506840. PMID: 39777347; PMCID: PMC11703891.
 8. Wichmann G, Wald T, Pirlich M, Stoehr M, Zebralla V, Kuhnt T, Nicolay NH, Hamsch P, Krücken I, Hoffmann KT, Lordick F, Kluge R, Wiegand S, **Dietz A**. Improved survival of locoregional-advanced larynx and hypopharynx cancer patients treated according to the DeLOS-II protocol. *Front Oncol.* 2024 Jun 11;14:1394691. doi: 10.3389/fonc.2024.1394691. PMID: 38919522; PMCID: PMC11198870.
 9. Singh P, McDonald L, Waldenberger D, Welslau M, von der Heyde E, Gauler T, **Dietz A**. Pooled analysis of nivolumab treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the United States and Germany. *Head Neck.* 2021 Nov;43(11):3540-3551. doi: 10.1002/hed.26853. Epub 2021 Sep 6. PMID: 34487397.
 10. **Dietz A**, Stöhr M, Zebralla V, Pirlich M, Wiegand S, Nicolay NH. Neck Dissection und adjuvante postoperative Therapie beim Oro- und Hypopharynxkarzinom: Empfehlungen der aktuellen S3-Leitlinie – Teil II [Surgical Treatment of Hypopharyngeal Carcinoma, Neck Dissection and Adjuvant Postoperative Therapy of Oropharyngeal and

Hypopharyngeal Cancer: Recommendations of the current S3 Guideline - Part II]. Laryngorhinootologie. 2024 Oct;103(10):734-753. German. doi: 10.1055/a-2223-4098. Epub 2024 Oct 1. PMID: 39353451.

Andreas Dietz PI in Current clinical trials

- OrigAMI-4: A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer - Initiierungstermin wird derzeit geplant, evtl. 11.11.2024
 - Cohort 1 (Amivantamab Monotherapy, Dose Expansion): Participants must have received prior treatment with platinum-based chemotherapy and a PD-1/PD-L1 inhibitor. Participant must have not received prior anti-EGFR therapy (inclusive of TKIs and antibodies) or more than 2 prior lines of systemic therapy for R/M HNSCC.
 - Cohort 2 (Pembrolizumab + Amivantamab, Dose Expansion Including Safety Run-in): Participants must be treatment-naïve in the R/M setting. Participants must have not received prior anti-EGFR therapy (inclusive of TKIs and antibodies) or anti-PD-1/PD-L1 therapy in the locally advanced setting. Participants must have a PD-L1 Combined Positive Score ≥ 1 within 3 months of the first dose of study treatment. A safety run-in (5 participants) will be conducted.
 - Cohorts 3A and 3B (Paclitaxel + Amivantamab, Dose Confirmation and Expansion): Participants must have received PD-1/PD-L1 based therapy. Participants must have not received prior anti-EGFR therapy (inclusive of TKIs and antibodies), taxane, or more than 2 prior lines of systemic therapy for R/M HNSCC. The dose confirmation Cohort 3A will first confirm the RP2CD(s) that will then be administered to additional participants in the dose expansion Cohort 3B.
- Seagen: A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2 – wir hatten Prof. Lordick unsere Unterstützung zugesagt, Initiierungstermin wird derzeit geplant, evtl. 09.12.2024
- Exelixis: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF ZANZALINTINIB (XL092) IN COMBINATION WITH PEMBROLIZUMAB VS PEMBROLIZUMAB IN THE FIRST-LINE TREATMENT OF SUBJECTS WITH PD-L1 POSITIVE RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA - Budget- und Vertragsverhandlung fast abgeschlossen
- Merus: A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice

monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma – derzeit mitten in den Budget- und Vertragsverhandlungen

- BMS-986340: A Phase 2, Single-blind, Randomized, Multicenter Study Assessing the Safety, Tolerability, and Efficacy of Nivolumab in Combination with BMS-986340 versus Nivolumab in Combination with Placebo as First-line Treatment for Participants with PD-L1 Positive, Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) – Unterlagen für Ethik eingereicht; bisher noch keine Vertragsverhandlungen
- Bicara: A Multicenter, Randomized, Double-Blind, Phase 2/3 Study of BCA101 or Placebo in Combination with Pembrolizumab for First Line Treatment of PD-L1-positive, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma – Vertragsverhandlung noch nicht gestartet, absagen?
- BI 1501-0002: A Phase Ib open label randomised 3 cohorts clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) – Pre Study Visite am 04.09.2024
- Regeneron: Study to evaluate Cemiplimab + Fianlimab efficacy in patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
- Elos (IIT Leipzig): Induction Chemotherapy with Docetaxel and Cisplatin (TP) followed by radiation compared to additional PD-1 inhibition in CPS $\geq$ 1 advanced laryngeal and hypopharyngeal cancer suitable for laryngectomy selected after short induction early response evaluation
- Ascendis: BelieveIT-201: A Randomized, Phase 2, Open-label Trial of TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ , TransCon IL-2 β/γ Monotherapy, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) – Initiierung am 23.09.2024; noch kein grünes Licht!
- BNT113-01: An open label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1
- Nykode VB-C-03: A Phase 1/2a, Open-label, Dose-finding Trial to Evaluate Safety, Immunogenicity, and Anti-tumor Activity of VB10.16 in Combination with Pembrolizumab in Patients with Unresectable Recurrent or Metastatic HPV16-positive Head and Neck Squamous Cell Carcinoma

- GSK219885 Galaxies: A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck